ホーム
探索
nav.journalClub
トレンド
その他
synapse
⌘+K
言語
日本語
日本語
Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: A 17-Year Single-Center Experience | Synapse
March 3, 2026
Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: A 17-Year Single-Center Experience
CT
Cristian Taborda
II
Iris Isufi
Yale Cancer Center
NB
Noffar Bar
Yale Cancer Center
See all
Key Points
Allogeneic transplantation shows promising clinical outcomes in acute lymphoblastic leukemia patients after 17 years.
The study highlights significant findings regarding graft-versus-host disease management and patient recovery.
Data collected over a 17-year single-center experience illustrates treatment effectiveness and patient survival rates.
These findings support the use of allogeneic transplantation, indicating potential for improved patient outcomes.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Taborda et al. (Sun,) studied this question.
synapsesocial.com/papers/69a7604cc6e9836116a2ce6d
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.168
Mark Helpful
Like
Save
Bookmark
Relay
Share